Colchicine treatment can be discontinued in a selected group of pediatric FMF patients

Table 3 Clinical scenarios that may trigger consideration for colchicine cessation trial when co-exist

1. Patients without biallelic MEFV pathogenic mutations (^a).
2. Patients with at least 4 years of remission under colchicine treatment.
3. Patients who required daily colchicine dose of 1 mg or less to maintain remission.
4. Absence of history of severe attacks (^b).

^aE148Q should not be considered as a pathogenic variant [10]
^bSevere Attacks = fever and two or more of the following: peritonitis, arthritis, pleuritis, erysipelas like erythema and orchitis

ISSN: 1546-0096